A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

Phase 4

Completed

• Conditions: Mucopolysaccharidosis VI; Maroteaux-Lamy Syndrome
• Interventions: Drug: Naglazyme

• Registration Number: NCT00299000
• Lead Sponsor: BioMarin Pharmaceutical

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.

Detailed Description

The primary objective of the study was to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.

The secondary objective of the study was to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources.

The safety objective of the study was to evaluate the safety of two dose levels of Naglazyme in infants under the age of one year who have MPS VI.

Study Timeline

• Study First Submitted: 2006-03-02
• Study First Submitted QC: 2006-03-02
• Study First Posted: 2006-03-06
• Study Start: 2006-05
• Primary Completion: 2009-04
• Study Completion: 2009-04
• Results First Submitted: 2010-05-07
• Results First Submitted QC: 2010-09-28
• Results First Posted: 2010-10-15
• Status Verified: 2011-07
• Last Update Submitted: 2011-07-19
• Last Update Posted: 2011-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Signed informed consent by a parent or legal guardian
• Parent or legal guardian willing and able to comply with all study procedures
• Equal to or greater than 36 weeks estimated gestational age by physical exam at birth
• Has a diagnosis of MPS VI based on a documented prenatal diagnosis or fibroblast or leukocyte N-acetylgalactosamine 4-sulfatase (ASB) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory
• Is less than one year of age
• Has no evidence of skeletal dysplasia based on physical exam

Read More

Exclusion Criteria

• Parent of legal guardian perceived to be unreliable or unavailable for study participation
• Use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
• Has concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation)
• Any condition that, in the view of the principle investigator, renders the subject at high risk from treatment compliance and/or completing the study
• Has known hypersensitivity to Naglazyme
• Has previously received Naglazyme

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Naglazyme, 1.0 mg/kg	Naglazyme	Dose comparison
Naglazyme, 2.0 mg/kg	Naglazyme	Dose Comparison

Primary Outcome Measures

Name	Time	Method
Change in Height	52 weeks
Change in Weight	52 weeks
Change in Haed Circumference	52 weeks

Secondary Outcome Measures

Name	Time	Method
Change in Urinary Glycosaminoglycan Levels	minimum 52 weeks of dosing	Change in urinary GAG levels was calculated from baseline to week 52 of treatment.

Trial Locations

Locations (4)

Hospital PediAtrico de Coimbra; 🇵🇹 Coimbra, Portugal

Children's Hospital Oakland; 🇺🇸 Oakland, California, United States

Hospital Femme Mere Enfant Centre; 🇫🇷 Lyon, France

Children's Hospital Los Angeles; 🇺🇸 Los Angeles, California, United States